certify that this correspondence is being deposited with the US Postal Service with sufficient postage as Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below. Date: August 19, 2003 PATENT Docket No. GC527-C1 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE In re Application of Group Art Unit: 1644 Estell et al. Examiner: Saunders, David Serial No.: 09/500,135 Filed: February 8, 2000 For: Proteins Producing an Altered Immunogenic Response and Methods of Making and Using) the Same Supplemental Information Disclosure Statement Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir: Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449 and attached thereto) of which they are aware, that they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56. This Information Disclosure Statement: (a) accompanies the new patent application submitted herewith. 37 CFR §1.97(a). (b) is filed within three months after the filing date of the application or within three months after the date of entry into the national stage of a PCT application as set forth in 37 CFR §1.491. (c) as far as is known to the undersigned, is filed before the mailing date of a first Office Action on the merits. (d) 🛛 is filed after the first Office Action and more than three months after the application filing date or PCT national stage date of entry filing but, as far

 	rejection or a notice of allowance, whichever occurs first, and is accompanied by either the fee (\$180.00) set forth in 37 CFR §1.17(p) or a certification as specified in 37 CFR §1.97(e), as checked below. Authorization to charge Deposit Account No. 07-1048 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement is provided in the Transmittal Letter submitted herewith in duplicate.					
į	is filed after the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by authorization (in the Transmittal Letter submitted herewith in duplicate) to charge Deposit Account No. 07-1048 the fee (\$180.00) set forth in 37 CFR §1.17(I)(1) and a certification as specified in 37 CFR §1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the Supplemental Information Disclosure Statement.					
[If either of bo	exes (d) or (e) is checked above, the following "certification" under 37 CFR					
§1.97(e) may i	need to be completed.] The undersigned certifies that:					
	Each item of information contained in the Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.					
	No item of information contained in this Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.					
A copy of the i	tems on Form PTO-1449 is supplied: PCT Written Opinion for					
	204, filed January 22, 2001 with attached patents and publications.					
	h ☐ none ☒ only those listed below:					
	and WO 99/06061					
A concise exp	lanation of relevance of the items listed on PTO-1449 is:					
,						
	given for each listed item					
	given for only non-English language listed item(s)					
	in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.					

Serial No. 09/50**O**, 135 Page 3

The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Date: August 19, 2003

Kamrin T. MacKnight Registration No. 38,230

Genencor International, Inc. 925 Page Mill Road Palo Alto, CA 94304-1013

Tel: 650 846-5838 Fax: 650 845-6504

Attorney Docket No.: GC527-CAPE									
	ket No.: GC527-C7	PEZ		Serial No.: 09/500,	,133				
Applicant: E	stell et al.	2 2000 E	-	10					
Applicant: Estell et al. Filing Date: February 8, 2000				Group: 1644					
Page 1 of 1				Date of this Submission: August 19, 2003					
		era inm	US PATENT I	DOCUMENTS					
Examiner's	Document					Sub-	Filing		
Initial	Number	Date	Name		Class	Class	Date		
		TILLE							
		<u>-</u>	DEIGN PATER	NT DOCUMENTS					
Examiner's	Document		REIGNFAILI	11 DOCUMENTO		Sub-	Translation		
Initials	Number	Date	Country		Class	Class	Yes/No		
	WO 95/05849	3/2/95	PCT		0,000	0.200			
		2/11/99	PCT						
	WO 99/06061	2/11/99	TFCI						
Examiner's Initials	Author, Title, Date, Pertinent Pages, etc.								
	Copy of Written Opinion for PCT/US01/02204								
, .,									
									
					<u> </u>				
						. = .			
				· · · · · · · · · · · · · · · · · · ·					
			·						
	<u></u>								
Examiner				Date Considered					

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. PTO-1449